Last updated: 2026-09-08 12:29:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Aprea Therapeutics, Inc. (APRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.86, with a market capitalization of $10.00M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.55 to $1.69. This page covers its latest market performance, valuation, price trends and company information.
$10.00M | |
$0.81 | |
$1,062.20 | |
$0.55 | |
-- | |
2.38K | |
227.91K | |
-- | |
$1.69 | |
$0.55 | |
-- | |
-- |
Aprea Therapeutics, Inc. (APRE) is trading at $0.80 in pre-market trading as of 2026-09-08 12:14:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing APRE before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, Aprea Therapeutics, Inc. (APRE) moved from $0.86 to $0.86, representing a decline of 0.36% ($0.00).
The stock traded between $0.78 and $0.99 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 406.81 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 27.1%
APRE is currently trading at $0.86, placing it 27.1% of the way from its 52-week low of $0.55 to its 52-week high of $1.69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aprea Therapeutics, Inc. (APRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.